Towards a Better Understanding of Cognitive Disturbances in Depressed Psychiatric Patients

Jointly provided by Postgraduate Institute for Medicine and Global Medical Education.

Supported by an independent educational grant from Forest, Jazz, Lundbeck, Merck, Sunovion, and Takeda pharmaceuticals.

Scroll to the Bottom of this Information to Begin this Course

Release date: June 30, 2015

Valid through: June 30, 2016

Specialty: Psychiatric Medicine

Topic: Depression

Media: Internet

Estimated Time to Complete Activity: 0.75 hours

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, and registered nurses involved in the care of patients with psychiatric illnesses.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the evidence base for the treatment of patients with bipolar depression, mixed episodes, and major depression, including cognitive disturbances.
  • Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics
  • Formulate appropriate treatment regimens considering the emergence of new investigative agents
  • Provide appropriate care and counsel for patients and their families.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credits
  • Nurses0.6 contact hours
  • Nurse Practitioners1.0 contact hours
    Designated for 0.31 contact hours of pharmacotherapy credit.

All other health care professionals completing this course will be issued a statement of participation.


Michael Thase, M.D.
Professor of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Philadelphia Veterans Affairs Medical Center
Pennsylvania, PA

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Global Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

This educational activity for 0.6 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AANP Credit

This program is approved for 1.0 contact hour of continuing education (which includes 0.31 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1501030. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Michael Thase, M.D.
  • Grant Support: Agency for Healthcare Research and Quality, Forest Pharmaceuticals, National Institute of Mental Health, Otsuka Pharmaceuticals
  • Royalties: American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.
  • Consultant: Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cerecor, Inc., Eli Lilly & Co., Dey Pharma, L.P., Forest Laboratories, Gerson Lehman Group, Guidepoint Global, H. Lundbeck A/S , MedAvante, Inc., Merck and Co. Inc. (formerly Schering Plough and Organon), Neuronetics, Inc., Otsuka, Ortho-McNeil Pharmaceuticals(Johnson & Johnson; Janssen), Pamlab, L.L.C., Pfizer (formerly Wyeth Ayerst Pharmaceuticals), PGx, Inc, Shire US Inc., Sunovion Pharmaceuticals, Inc., Supernus Pharmaceuticals, Takeda, Transcept Pharmaceuticals
  • Stock Ownership: MedAvante, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Global Medical Education (GME) planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Prakash Masand, MD: Consultant: Forest, Lundbeck, Merck, Pamlab, Pfizer, Sunovion, Takeda; Research Support: Forest; Speaker’s Bureau: Forest, GlaxoSmithKline, Lundbeck, Merck, Pamlab, Pfizer, Sunovion, Takeda.

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period June 2015 through June 30, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.